The experience of using a bacteriophages-based complex antibacterial and analgesic drug in gel formulation in women who underwent various instrumental and diagnostic and treatment interventions

Cover Page

Abstract


During the spread of bacterial infections with extensive drug resistance, the potential of existing antibacterial drugs is significantly reduced. The medical community is seeking opportunities for the rational use of antibacterial drugs, the development of new drugs, as well as the use of alternative treatments for these infections.

Aim. The objective of this study was to evaluate the effectiveness of the use of a complex antibacterial and analgesic drug based on bacteriophages in gel form during various instrumental studies and diagnostic procedures in order to minimize the risk of the urinary system infections complications.

Materials and methods. The study included 235 women aged 18 to 75 years who underwent treatment at the Moscow State Clinical Hospital named after Spasokukotsky and in the clinic of urology of Moscow State University of Medicine and Dentistry from September 2019 to January 2020. During the manipulation, all patients of the main group (n=120) used a developed preparation based on bacteriophages, and in the control group (n=115), a topical gel based on chlorhexidine dihydrochloride and lidocaine hydrochloride was used. All patients before the manipulation, as well as 10 days after the manipulation, underwent bacteriological analysis of urine. Efficiency assessment was carried out on the basis of laboratory data obtained, as well as according to the visual analogue scale of the pain syndrome severity.

Results. None of the patients in the main group showed intolerance, side effects and allergic reactions of the developed drug based on bacteriophages. Bacteriological analysis of urine received before manipulation in both groups showed the absence of clinically significant titers of pathogenic bacteria, while 1 week after manipulation the number of titers of pathogenic bacteria (≥104) was significantly higher in the control group (p>0.04). In patients of the main group, the incidence of dysuria was lower compared with the control group (p<0.05).

Conclusion. The study showed good tolerance of the developed drug and its clinical effectiveness in reducing the number of symptomatic bacteriuria; severity of pain after undergoing manipulation was relatively lower in the main group of patients. Conducting multicenter studies with the inclusion of a larger number of patients in the future will reduce the economic costs associated with treating patients by reducing the number of cases of nosocomial infections and reducing postoperative time spent by patients in the hospital.


Full Text

Restricted Access

About the authors

Alexander O. Vasilyev

Yevdokimov Moscow State University of Medicine and Dentistry; Research Institute of Health Organization and Medical Management; Spasokukotsky City Clinical Hospital

Author for correspondence.
Email: kalinina@outlook.com
ORCID iD: 0000-0001-5468-0011

Russian Federation, Moscow

Cand. Sci. (Med.)

 

Natalia A. Sazonova

Yevdokimov Moscow State University of Medicine and Dentistry

Email: kalinina@outlook.com
ORCID iD: 0000-0003-1673-1089

Russian Federation, Moscow

Clinical Resident

Vladimir D. Melnikov

Yevdokimov Moscow State University of Medicine and Dentistry

Email: kalinina@outlook.com
ORCID iD: 0000-0002-2403-4331

Russian Federation, Moscow

Clinical Resident

Amir F. Gabdullin

Yevdokimov Moscow State University of Medicine and Dentistry

Email: kalinina@outlook.com
ORCID iD: 0000-0002-9989-7879

Russian Federation, Moscow

Clinical Resident

Andrei V. Zaitsev

Yevdokimov Moscow State University of Medicine and Dentistry; Spasokukotsky City Clinical Hospital

Email: kalinina@outlook.com

Russian Federation, Moscow

D. Sci. (Med.), Prof.

Arseniy A. Shiryaev

Yevdokimov Moscow State University of Medicine and Dentistry; Spasokukotsky City Clinical Hospital

Email: kalinina@outlook.com
ORCID iD: 0000-0003-0680-9460

Russian Federation, Moscow

Graduate Student

 

Yuriy A. Kim

Yevdokimov Moscow State University of Medicine and Dentistry; Spasokukotsky City Clinical Hospital

Email: kalinina@outlook.com
ORCID iD: 0000-0001-6390-3408

Russian Federation, Moscow

Graduate Student

Elena A. Prilepskaya

Yevdokimov Moscow State University of Medicine and Dentistry; Spasokukotsky City Clinical Hospital

Email: kalinina@outlook.com
ORCID iD: 0000-0003-4599-6094

Russian Federation, Moscow

Senior Assistant, Graduate Student

Dmitry Yu. Pushkar

Yevdokimov Moscow State University of Medicine and Dentistry; Spasokukotsky City Clinical Hospital

Email: kalinina@outlook.com
ORCID iD: 0000-0002-6096-5723

Russian Federation, Moscow

D. Sci. (Med.), Prof., Acad. RAS

References

  1. Колонтарев К.Б. Обзор клинических рекомендаций по лечению острой неосложненной инфекции нижних мочевых путей. Эффективная фармакотерапия. 2015; 3: 6–14.
  2. [Kolontarev K.B. Obzor klinicheskikh rekomendatsii po lecheniiu ostroi neoslozhnennoi infektsii nizhnikh mochevykh putei. Effektivnaia farmakoterapiia. 2015; 3: 6–14 (in Russian).]
  3. Arshad M, Seed PC. Urinary tract infections in the infant. Clin Perinatol 2015; 42 (1): 17–28.
  4. Stamm WE, Norrby SR. Urinary tract infections: disease panorama and challenges. J Infect Dis 2001; 183 (Suppl 1.):S1–4.
  5. Лоран О.Б., Синякова Л.А., Косова И.В. Рецидивирующие инфекции мочевых путей. Алгоритм диагностики и лечения. М.: МИА, 2008.
  6. [Laurent O.B., Sinyakova L.A., Kosova I.V. Recurrent urinary tract infections. Algorithm for diagnosis and treatment. Moscow: MIA, 2008 (in Russian).]
  7. Nappi RE, Palacios S. Impact of vulvovaginal atrophy on sexual health and quality of life at postmenopause. Climacteric 2014; 17 (1): 3–9. doi: 10.3109/13697137.2013.871696
  8. Santajit S, Indrawattana N. Mechanisms of Antimicrobial Resistance in ESKAPE Pathogens. BioMed Res Int 2016; p. 1–8.
  9. Эйдельштейн М.В., Сухорукова М.В., Склеенова Е.Ю. и др. Антибиотикорезистентность нозокомиальных штаммов Pseudomonas aeruginosa в стационарах России: результаты многоцентрового эпидемиологического исследования «Марафон» 2013–2014. Клин. микробиология и антимикробная химиотерапия. 2017; 19 (1): 37–41.
  10. [Eidel’shtein M.V., Sukhorukova M.V., Skleenova E.Iu. et al. Antibiotikorezistentnost’ nozokomial’nykh shtammov Pseudomonas aeruginosa v statsionarakh Rossii: rezul’taty mnogotsentrovogo epidemiologicheskogo issledovaniia «Marafon» 2013–2014. Klin. mikrobiologiia i antimikrobnaia khimioterapiia. 2017; 19 (1): 37–41 (in Russian).]
  11. Kutateladze M, Adamia R. Bacteriophages as Potential New Therapeutics to Replace or Supplement Antibiotics. Trends Biotechnol 2010; 28: 591–5.
  12. Miedzybrodzki R, Hoyle N, Zhvaniya F et al. Current Updates from the Long-standing Phage Research Centers in Georgia, Poland and Russia. In Bacteriophages; Harper, D., Abedon, S., Burrowes, B., Eds.; Springer: Cham, Switzerland, 2018; p. 1–31.
  13. Antibiotic Resistance Threats in the United States; U.S. Department of Health and Human Services, CDC: Atlanta, GA, USA, 2019.
  14. Ширяев А.А., Васильев А.О., Зайцев А.В. и др. Перспектива применения бактериофагов в урологической практике. Урология. 2019; 6: 131–6.
  15. [Shiriaev A.A., Vasil’ev A.O., Zaitsev A.V. et al. Perspektiva primeneniia bakteriofagov v urologicheskoi praktike. Urologiia. 2019; 6: 131–6 (in Russian).]
  16. Howell AB, Reed JD, Kreuger CG et al. A-type cranberry proanthocyanidins and uropathogenic bacterial anti- adhesion activity. Phytochemistry 2005; 66: 2281–91. doi: 10.1016/j.phytochem.2005.05.022
  17. Singh I, Gautam LK, Kaur IR. Effect of oral cranberry extract (standardized proanthocyanidin-A) in patients with recurrent UTI by pathogenic E. coli: a randomized placebo-controlled clinical research study. Int Urol Nephrol 2016; 48: 1379–86. doi: 10.1007/s11255-016-1342-8
  18. Vostalova J, Vidlar A, Simanek V et al. Are high proanthocyanidins key to Cranberry efficacy in the prevention of recurrent urinary tract infection? Phytother Res 2015; 29: 1559–67. doi: 10.1002/ptr.5427
  19. Naber KG. Efficacy and safety of the phytotherapeutic drug Canephron N in prevention and treatment of urogenital and gestational disease: review of clinical experience in Eastern Europe and Central Asia. Res Rep Urol 2013; 5: 39–46.
  20. Miotla P, Wawrysiuk S, Naber K et al. Should we always use antibiotics after urodynamic studies in high-risk patients? Biomed Res Int 2018; 2018: 1607425. doi: 10.1155/2018/1607425
  21. Wagenlehner FM, Abramov-Sommariva D, Höller M, Steindl H et al. Non-Antibiotic Herbal Therapy (BNO 1045) versus antibiotic therapy (Fosfomycin Trometamol) for the treatment of acute lower uncomplicated urinary tract infections in women: a double-blind, parallel-group, randomized, multicentre non-inferiority phase III trial. Urol Int 2018; 101: 327–36. doi: 10.1159/000493368
  22. Stapleton AE. The vaginal microbiota and urinary tract infection. Microbiol Spectr 2016. doi: 10.1128/microbiolspec.UTI-0025-2016
  23. Beerepoot MA, ter Riet G, Nys S et al. Lactobacilli vs antibiotics to prevent urinary tract infections: a randomized, double-blind, noninferiority trial in postmenopausal women. Arch Intern Med 2012; 172: 704–12. doi: 10.1001/archinternmed.2012.777
  24. Schwenger EM, Tejani AM, Loewen PS. Probiotics for Preventing Urinary Tract Infections in Adults and Children. Cochrane Database Syst Rev 2015; 12: CD008772. doi: 10.1002/14651858.CD008772.pub2
  25. Gupta V, Nag D, Garg P. Recurrent urinary tract infections in women: how promising is the use of probiotics? Indian J Med Microbiol 2017; 35: 347–54. doi: 10.4103/ijmm.IJMM_16_292
  26. Vane JR, Botting RM. Mechanism of action of nonsteroidal anti-inflammatory drugs. Am J Med 1998; 104 (3A): 2S–8S. doi: 10.1016/S0002-9343(97)00203-9
  27. Gagyor I, Bleidorn J, Kochen MM et al. Ibuprofen versus fosfomycin for uncomplicated urinary tract infection in women: randomised controlled trial. BMJ 2015; 351: h6544.
  28. Bleidorn J, Hummers-Pradier E, Schmie-Mann G et al. Recurrent urinary tract infections and complications after symptomatic versus antibiotic treatment: fol-low-up of a randomised controlled trial. Ger Med Sci 2016; 14: Doc01.
  29. Kronenberg A, Butikofer L, Odutayo A et al. Symptomatic treatment of uncomplicated lower urinary tract infections in the ambulatory setting: randomised, double blind trial. BMJ 2017; 359: j4784. doi: 10.1136/bmj.j4784
  30. Altarac S, Papes D. Use of d-mannose in prophylaxis of recurrent urinary tract infections (UTIs) in women. BJU Int 2014; 113: 9–10.
  31. Perrotta C, Aznar M, Mejia R et al. Oestrogens for preventing recurrent urinary tract infection in postmenopausal women. Cochrane Database Syst Rev 2008; 2008: CD005131.
  32. Hickling DR, Nitti VW. Management of recurrent urinary tract infections in healthy adult women. Rev Urol 2013; 15: 41–8.
  33. Simon JA, Altomare C, Cort S et al. Overall safety of ospemifene in postmenopausal women from placebo-controlled phase 2 and 3 trials.
  34. J Womens Health (Larchmt) 2018; 27: 14–23.
  35. Carlsson S, Wiklund NP, Engstrand L et al. Effects of pH, nitrite, and ascorbic acid on nonenzymatic nitric oxide generation and bacterial growth in urine. Nitric Oxide 2001; 5: 580–6.
  36. doi: 10.1006/niox.2001.0371
  37. Nseir W, Taha M, Nemarny H, Mograbi J. The association between serum levels of Vitamin D and recurrent urinary tract infections in premenopausal women. Int J Infect Dis 2013; 17: e1121–4.
  38. Hertting O, Lüthje P, Sullivan D et al. Vitamin D-deficient mice have more invasive urinary tract infection. PLoS One 2017; 12 (7): e0180810. doi: 10.1371/journal.pone.0180810
  39. Schmidhammer S, Ramoner R, Holtl L et al. An Escherichia coli-based oral vaccine against urinary tract infections potently activates human dendritic cells. Urology 2002; 60: 521–6. doi: 10.1016/S0090-4295(02)01767-3
  40. Magistro G, Stief CG. Vaccine development for urinary tract infections: where do we stand? Eur Urol Focus 2019; 5: 39–41.
  41. doi: 10.1016/j.euf.2018.07.034

Statistics

Views

Abstract - 60

PDF (Russian) - 0

Cited-By


PlumX

Dimensions

Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies